

old

804 1646

**TRANSMITTAL LETTER**  
**(General - Patent Pending)**

Docket No.  
11373

In Re Application of Tracy Willson, et al.

Serial No.  
09/051,843

Filing Date  
June 29, 1998

Examiner  
N. Basi

Group Art Unit  
1646

Title: **NOVEL HAEMOPOIETIN RECEPTOR AND GENETIC SEQUENCES ENCODING SAME**

JAN 17 1999

GROUP 18

TO THE ASSISTANT COMMISSIONER FOR PATENTS:

Transmitted herewith is: **Sequence Listing**

in the above identified application.

- ☒ No additional fee is required.
- ☐ A check in the amount of \_\_\_\_\_ is attached.
- ☒ The Assistant Commissioner is hereby authorized to charge and credit Deposit Account No. **19-1013/SSMP** as described below. A duplicate copy of this sheet is enclosed.
- ☐ Charge the amount of \_\_\_\_\_
- ☐ Credit any overpayment.
- ☒ Charge any additional fee required.

Signature

Dated: **January 4, 1999**

**Leopold Presser**  
**Registration No.: 19,827**

**SCULLY, SCOTT, MURPHY & PRESSER**  
**400 Garden City Plaza**  
**Garden City, New York 11530**  
**(516) 742-4343**

I certify that this document and fee is being deposited on 1/4/99 with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Signature of Person Mailing Correspondence

**Leopold Presser**

Typed or Printed Name of Person Mailing Correspondence

CC:



#92 m/Dist  
Gochum 01/11/99

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Tracy Willson, et al. Art Unit: 1646  
Serial No.: 09/051,843 Docket: 11373  
Filed: June 29, 1998 Dated: January 4, 1999  
For: NOVEL HAEMOPOIETIN RECEPTOR  
AND GENETIC SEQUENCES ENCODING  
SAME


Assistant Commissioner for Patents  
Washington, D.C. 20231

VERIFICATION UNDER 37 C.F.R. § 1.821(f)

Sir:

I hereby state that the content of the substitute paper and the substitute computer readable copies of the Sequence Listing submitted in accordance with 37 C.F.R. § 1.821(c) and (e), respectively, are the same.

Respectfully submitted,


  
Leopold Presser  
Registration No. 19,827

SCULLY, SCOTT, MURPHY & PRESSER  
400 Garden City Plaza  
Garden City, New York 11530  
(516) 742-4343  
PIB:bb

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, DC 20231 on January 4, 1999.

Dated: January 4, 1999

  
Leopold Presser



PATENTS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Tracy Willson, et al. Art Unit: 1646

Serial No.: 09/051,843

Docket: 11373

Filed: June 29, 1998

Dated: January 4, 1999

For: NOVEL HAEMOPOIETIN RECEPTOR  
AND GENETIC SEQUENCES ENCODING  
SAME

Assistant Commissioner for Patents  
Washington, DC 20231

JAN 11 1999

IP 18

RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS  
FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE  
SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Sir:

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures dated December 2, 1998, applicants submit this letter.


Pursuant to 37 C.F.R. §1.821(e), applicants hereby submit a copy of the computer readable form of the Sequence Listing in the above-identified patent application. Pursuant to 37 C.F.R. §1.821(c), applicants hereby submit a paper copy of the Sequence Listing.

---

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, DC 20231 on January 4, 1999.


Dated: January 4, 1999

  
\_\_\_\_\_  
Leopold Presser

In accordance with 37 C.F.R. §1.821(f), I hereby state that the computer readable form of the Sequence Listing filed herewith is the same as the paper copy of the Sequence Listing also filed herewith, and further that no new matter is presented by this submission.

A copy of the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures is enclosed. Any additional fees associated with this submission may be charged to Deposit Account No. 19-1013/SSMP. A duplicate copy of this sheet is enclosed.

Respectfully submitted,



Leopold Presser  
Registration No. 19,827

SCULLY, SCOTT, MURPHY & PRESSER  
400 Garden City Plaza  
Garden City, New York 11530  
(516) 742-4343

PIB:bb



Application No.: 09/05189

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s)

- ☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☒ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☐ 7. Other: \_\_\_\_\_

**Applicant Must Provide:**

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☐ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).


For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

For PatentIn software help, call (703) 308-6856

**PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE**



**UNITED STATES DEPARTMENT OF COMMERCE  
Patent and Trademark Office**

Address: COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

APPLICATION NO.	FILED DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.
-----------------	------------	----------------------	---------------------

HM11/1202  
SCULLY SCOTT MURPHY & PRESSER  
400 GARDEN CITY PLAZA  
GARDEN CITY NY 11530

EXAMINER
----------

ART UNIT	PAPER NUMBER
----------	--------------

DATE MAILED: 12/02/98

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks



CEA/FA-1994

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.



EXAMINER	
ART UNIT	PAPER NUMBER

DATE MAILED:

Please find below a communication from the EXAMINER in charge of this application  
Commissioner of Patents.

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures.

Applicant is given ONE MONTH, or THIRTY DAYS, whichever is longer, from the mailing date of this letter within which to comply with the sequence rules, 37 CFR 1.821 - 1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a). In no case may an applicant extend the period for reply beyond the SIX MONTH statutory period. Direct the reply to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the reply.

Any inquiry concerning this communication should be directed to  
at telephone number (703)30